AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $19.3333.

ANGO has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Canaccord Genuity Group increased their price target on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a report on Friday.

Insider Transactions at AngioDynamics

In related news, SVP Lawrence T. Weiss acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, October 21st. The stock was bought at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the purchase, the senior vice president directly owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 6.00% of the stock is owned by corporate insiders.

Institutional Trading of AngioDynamics

Large investors have recently made changes to their positions in the company. State of Alaska Department of Revenue acquired a new stake in shares of AngioDynamics in the 3rd quarter worth $25,000. Washington Trust Advisors Inc. acquired a new position in shares of AngioDynamics during the third quarter worth about $27,000. State of Wyoming purchased a new position in AngioDynamics during the second quarter worth about $31,000. Russell Investments Group Ltd. lifted its position in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Trading Up 3.2%

Shares of ANGO opened at $10.18 on Tuesday. The firm has a market capitalization of $419.62 million, a price-to-earnings ratio of -15.19 and a beta of 0.47. The firm’s fifty day simple moving average is $12.53 and its 200-day simple moving average is $11.01. AngioDynamics has a twelve month low of $8.27 and a twelve month high of $13.99.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, January 6th. The medical instruments supplier reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05). AngioDynamics had a negative net margin of 9.02% and a negative return on equity of 2.28%. The business had revenue of $79.43 million during the quarter, compared to analysts’ expectations of $76.43 million. During the same period last year, the company earned ($0.04) EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. On average, analysts predict that AngioDynamics will post -0.37 earnings per share for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.